Prostate Cancer Prevention

Strategies and Realities

Robert G. Uzzo, Vladimir Kolenko, Deborah Watkins-Bruner, Paul F. Engstrom, Eric M. Horwitz, Andre Konski, Alan Pollack

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

The molecular and genetic events underlying prostate cancer begin decades before clinically significant disease is detected. The interaction of genetics and environmental influences in the development of prostate cancer is significant given the prolonged natural history of the disease. Most risk factors associated with significant prostate cancers including age, race, and genetics are non-modifiable. However, there is a growing awareness of modifiable risk factors such as diet and environmental factors, which require systematic study. Most previous disease prevention strategies have focused primarily on avoidance behaviors. However, currently, chemopreventive agents are increasingly used to disrupt one or more steps involved in carcinogenesis. The molecular targets for candidate prostate cancer prevention agents include sex steroid signaling differentiation and proliferation, angiogenesis, and pro-apoptotic pathways. Prostate cancer risk assessment programs such as the Prostate Cancer Risk Assessment Program (PRAP) and Prostate Cancer Risk Registry (PCRR) provide integrated multidisciplinary approaches to screening, counseling, and researching preventive efforts. For prostate-cancer-prevention efforts to be successful, they must be studied systematically across multiple medical, social, and economic disciplines. Chemopreventive strategies must start early in the disease process and follow-up must be rigorous and extend over decades. Programs such as PCRR and PRAP must be integrated into NCI-sponsored studies, such as SELECT and Prostate Cancer Prevention Trial (PCPT). Finally, chemoprevention and risk assessment programs must serve as a catalyst for the development of educational training tools directed toward community-based health care professionals and their patients.

Original languageEnglish
Title of host publicationProstate Cancer: Science and Clinical Practice
PublisherElsevier Ltd.
Pages89-99
Number of pages11
ISBN (Print)9780122869815
DOIs
StatePublished - Jul 1 2003
Externally publishedYes

Fingerprint

Risk assessment
Prostatic Neoplasms
Nutrition
Health care
Screening
Steroids
Registries
Economics
Catalysts
Avoidance Learning
Medical Economics
Community Health Services
Chemoprevention
Counseling
Molecular Biology
Carcinogenesis
Genetics
Diet

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Uzzo, R. G., Kolenko, V., Watkins-Bruner, D., Engstrom, P. F., Horwitz, E. M., Konski, A., & Pollack, A. (2003). Prostate Cancer Prevention: Strategies and Realities. In Prostate Cancer: Science and Clinical Practice (pp. 89-99). Elsevier Ltd.. https://doi.org/10.1016/B978-012286981-5/50012-4

Prostate Cancer Prevention : Strategies and Realities. / Uzzo, Robert G.; Kolenko, Vladimir; Watkins-Bruner, Deborah; Engstrom, Paul F.; Horwitz, Eric M.; Konski, Andre; Pollack, Alan.

Prostate Cancer: Science and Clinical Practice. Elsevier Ltd., 2003. p. 89-99.

Research output: Chapter in Book/Report/Conference proceedingChapter

Uzzo, RG, Kolenko, V, Watkins-Bruner, D, Engstrom, PF, Horwitz, EM, Konski, A & Pollack, A 2003, Prostate Cancer Prevention: Strategies and Realities. in Prostate Cancer: Science and Clinical Practice. Elsevier Ltd., pp. 89-99. https://doi.org/10.1016/B978-012286981-5/50012-4
Uzzo RG, Kolenko V, Watkins-Bruner D, Engstrom PF, Horwitz EM, Konski A et al. Prostate Cancer Prevention: Strategies and Realities. In Prostate Cancer: Science and Clinical Practice. Elsevier Ltd. 2003. p. 89-99 https://doi.org/10.1016/B978-012286981-5/50012-4
Uzzo, Robert G. ; Kolenko, Vladimir ; Watkins-Bruner, Deborah ; Engstrom, Paul F. ; Horwitz, Eric M. ; Konski, Andre ; Pollack, Alan. / Prostate Cancer Prevention : Strategies and Realities. Prostate Cancer: Science and Clinical Practice. Elsevier Ltd., 2003. pp. 89-99
@inbook{284ebc7960ca41d999961fcdfc479f17,
title = "Prostate Cancer Prevention: Strategies and Realities",
abstract = "The molecular and genetic events underlying prostate cancer begin decades before clinically significant disease is detected. The interaction of genetics and environmental influences in the development of prostate cancer is significant given the prolonged natural history of the disease. Most risk factors associated with significant prostate cancers including age, race, and genetics are non-modifiable. However, there is a growing awareness of modifiable risk factors such as diet and environmental factors, which require systematic study. Most previous disease prevention strategies have focused primarily on avoidance behaviors. However, currently, chemopreventive agents are increasingly used to disrupt one or more steps involved in carcinogenesis. The molecular targets for candidate prostate cancer prevention agents include sex steroid signaling differentiation and proliferation, angiogenesis, and pro-apoptotic pathways. Prostate cancer risk assessment programs such as the Prostate Cancer Risk Assessment Program (PRAP) and Prostate Cancer Risk Registry (PCRR) provide integrated multidisciplinary approaches to screening, counseling, and researching preventive efforts. For prostate-cancer-prevention efforts to be successful, they must be studied systematically across multiple medical, social, and economic disciplines. Chemopreventive strategies must start early in the disease process and follow-up must be rigorous and extend over decades. Programs such as PCRR and PRAP must be integrated into NCI-sponsored studies, such as SELECT and Prostate Cancer Prevention Trial (PCPT). Finally, chemoprevention and risk assessment programs must serve as a catalyst for the development of educational training tools directed toward community-based health care professionals and their patients.",
author = "Uzzo, {Robert G.} and Vladimir Kolenko and Deborah Watkins-Bruner and Engstrom, {Paul F.} and Horwitz, {Eric M.} and Andre Konski and Alan Pollack",
year = "2003",
month = "7",
day = "1",
doi = "10.1016/B978-012286981-5/50012-4",
language = "English",
isbn = "9780122869815",
pages = "89--99",
booktitle = "Prostate Cancer: Science and Clinical Practice",
publisher = "Elsevier Ltd.",

}

TY - CHAP

T1 - Prostate Cancer Prevention

T2 - Strategies and Realities

AU - Uzzo, Robert G.

AU - Kolenko, Vladimir

AU - Watkins-Bruner, Deborah

AU - Engstrom, Paul F.

AU - Horwitz, Eric M.

AU - Konski, Andre

AU - Pollack, Alan

PY - 2003/7/1

Y1 - 2003/7/1

N2 - The molecular and genetic events underlying prostate cancer begin decades before clinically significant disease is detected. The interaction of genetics and environmental influences in the development of prostate cancer is significant given the prolonged natural history of the disease. Most risk factors associated with significant prostate cancers including age, race, and genetics are non-modifiable. However, there is a growing awareness of modifiable risk factors such as diet and environmental factors, which require systematic study. Most previous disease prevention strategies have focused primarily on avoidance behaviors. However, currently, chemopreventive agents are increasingly used to disrupt one or more steps involved in carcinogenesis. The molecular targets for candidate prostate cancer prevention agents include sex steroid signaling differentiation and proliferation, angiogenesis, and pro-apoptotic pathways. Prostate cancer risk assessment programs such as the Prostate Cancer Risk Assessment Program (PRAP) and Prostate Cancer Risk Registry (PCRR) provide integrated multidisciplinary approaches to screening, counseling, and researching preventive efforts. For prostate-cancer-prevention efforts to be successful, they must be studied systematically across multiple medical, social, and economic disciplines. Chemopreventive strategies must start early in the disease process and follow-up must be rigorous and extend over decades. Programs such as PCRR and PRAP must be integrated into NCI-sponsored studies, such as SELECT and Prostate Cancer Prevention Trial (PCPT). Finally, chemoprevention and risk assessment programs must serve as a catalyst for the development of educational training tools directed toward community-based health care professionals and their patients.

AB - The molecular and genetic events underlying prostate cancer begin decades before clinically significant disease is detected. The interaction of genetics and environmental influences in the development of prostate cancer is significant given the prolonged natural history of the disease. Most risk factors associated with significant prostate cancers including age, race, and genetics are non-modifiable. However, there is a growing awareness of modifiable risk factors such as diet and environmental factors, which require systematic study. Most previous disease prevention strategies have focused primarily on avoidance behaviors. However, currently, chemopreventive agents are increasingly used to disrupt one or more steps involved in carcinogenesis. The molecular targets for candidate prostate cancer prevention agents include sex steroid signaling differentiation and proliferation, angiogenesis, and pro-apoptotic pathways. Prostate cancer risk assessment programs such as the Prostate Cancer Risk Assessment Program (PRAP) and Prostate Cancer Risk Registry (PCRR) provide integrated multidisciplinary approaches to screening, counseling, and researching preventive efforts. For prostate-cancer-prevention efforts to be successful, they must be studied systematically across multiple medical, social, and economic disciplines. Chemopreventive strategies must start early in the disease process and follow-up must be rigorous and extend over decades. Programs such as PCRR and PRAP must be integrated into NCI-sponsored studies, such as SELECT and Prostate Cancer Prevention Trial (PCPT). Finally, chemoprevention and risk assessment programs must serve as a catalyst for the development of educational training tools directed toward community-based health care professionals and their patients.

UR - http://www.scopus.com/inward/record.url?scp=2942589404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942589404&partnerID=8YFLogxK

U2 - 10.1016/B978-012286981-5/50012-4

DO - 10.1016/B978-012286981-5/50012-4

M3 - Chapter

SN - 9780122869815

SP - 89

EP - 99

BT - Prostate Cancer: Science and Clinical Practice

PB - Elsevier Ltd.

ER -